Nadler Financial Group Inc. Has $783,000 Position in Pfizer Inc. (NYSE:PFE)

Nadler Financial Group Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 5.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,207 shares of the biopharmaceutical company’s stock after selling 1,712 shares during the period. Nadler Financial Group Inc.’s holdings in Pfizer were worth $783,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Briaud Financial Planning Inc acquired a new position in Pfizer in the 3rd quarter valued at $30,000. GoalVest Advisory LLC raised its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new position in Pfizer in the 3rd quarter valued at $34,000. VisionPoint Advisory Group LLC raised its holdings in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in Pfizer in the 4th quarter valued at $36,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.7 %

Shares of NYSE PFE traded up $0.17 during trading on Friday, reaching $25.43. The company had a trading volume of 16,484,856 shares, compared to its average volume of 41,614,098. The company’s fifty day moving average price is $27.01 and its 200-day moving average price is $28.48. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The stock has a market cap of $144.00 billion, a P/E ratio of 70.39, a PEG ratio of 1.18 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the company posted $1.14 EPS. The business’s revenue was down 41.3% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.61%. Pfizer’s payout ratio is 466.67%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.